Human Multidrug Resistance Protein 4 (MRP4) (SJ-98-0013)

St. Jude Reference #SJ-98-0013


The human multidrug resistance protein 4 (MRP4), a member of the ATP-binding cassette (ABC) transporter superfamily is involved in the efflux of antiretroviral drugs such as PMEA and AZT, drugs used in the treatment of HIV infections. MRP4 overexpression causes increased efflux of such drugs from the cell allowing the growth of HIV. MRP4 expression could also affect the efficacy of nucleoside analogs used to treat other diseases such as herpesvirus infections, hepatitis B virus infections, and cancer. The MRP4 technology could be used by the pharmaceutical industry to identify patients who are resistant and those who are likely to develop resistance to antiretroviral drug therapy, as well as for other applications relating to drug development.



Drug resistance, transporter, HIV, cancer, drug development


Granted Patents or Published Applications

U.S. Patent No. 6,759,238


Related Scientific References

Schuetz, John D., et al. "MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs" Nature Medicine 5:1048-1051 (1999).


Licensing Opportunities

We are currently seeking licensing opportunities in all fields for the development of this technology. Contact:

Related Links

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.